Back

Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Young Investigator Award Session Thrombosis Secondary Prevention ESC Premium Access ESC Congress 2019

About the speaker

Photo
Miss Tamar de Vries

University Medical Center Utrecht, Utrecht (Netherlands (The))

3 More presentations in this session

Presentation thumbnail
The prothrombotic transcriptome of reticulated platelets
Doctor D. Bongiovanni (Augsburg, DE)
Abstract Slides Video
Presentation thumbnail
Sirtuin 5 regulates arterial thrombosis by modulating endothelial plasminogen activator inhibitor-1
Doctor L. Liberale (Genova, IT)
Abstract Slides Video
Presentation thumbnail
Intravenous administration of IV-STATIN CARDIOSHIELD during myocardial infarction renders higher cardioprotection than oral atorvastatin given shortly after reperfusion: a translational CMR study
Doctor G. Mendieta Badimon (Barcelona, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Award Session Thrombosis

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
Making personalised prevention everyone's business
thumbnail
Congress Presentation
Should we intervene early in patients with asymptomatic aortic stenosis?
thumbnail
Congress Presentation
Cardiovascular prevention in older adults

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources